Not Tagged
TORL BioTherapeutics
[]
torl biotherapeutics reveals promising initial results of their novel cldn6 targeted adc, torl-1-23, selected for presentation at the prestigious 2023 asco annual meeting. for more information, visit the #database at 
By discovering the latest data on pharmaceutical #Clinical #Patent #News #indication #Pipeline to empower IP and R&D teams make more strategic decisions.